<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601965</url>
  </required_header>
  <id_info>
    <org_study_id>R34MH080151</org_study_id>
    <secondary_id>R34MH080151</secondary_id>
    <nct_id>NCT00601965</nct_id>
  </id_info>
  <brief_title>Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults</brief_title>
  <official_title>CBT Augmentation of SSRI Treatment for Geriatric GAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Veterans Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether adding cognitive behavioral therapy to the antidepressant
      escitalopram is effective in reducing anxiety in older adults with generalized anxiety
      disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Generalized anxiety disorder (GAD) affects nearly 6.8 million adults in the United States.
      GAD is diagnosed when a person spends at least 6 months excessively worrying over everyday
      problems to the point that carrying out normal life becomes difficult. People with GAD face
      each day with intense anxiety and tension and are unable to alleviate their worries. Physical
      symptoms of GAD include muscle aches, nausea, sweating, exhaustion, irritability, frequent
      urination, shaking, and hot flashes. People with GAD often experience other anxiety
      disorders, depression, or substance abuse, all of which can worsen symptoms of GAD. This
      makes early and appropriate treatment for GAD important. Current treatments for GAD include
      medication and/or types of psychotherapy. This study will assess whether adding cognitive
      behavioral therapy (CBT) to the antidepressant escitalopram is effective in reducing anxiety
      in older adults with GAD.

      Participation in this double-blind study will last up to 13 months. Participants will be
      asked to stop any current treatments for anxiety or depression for the duration of the study.
      Participants will begin taking one pill of the medication escitalopram daily for 12 weeks.
      Dosage will be increased to two pills each day if symptoms do not improve within 4 weeks.
      After 12 weeks, all participants will continue taking escitalopram for an additional 16
      weeks. In addition, some participants will be randomly assigned to receive 16 weekly sessions
      of CBT, lasting 1 hour each. CBT sessions will involve learning relaxation techniques and
      other skills to manage anxiety and completing 30-minute at-home practice assignments each
      day. A family member will accompany participants to the first four CBT sessions. All
      participants will be asked to provide information for a close contact, who will be
      interviewed at baseline, Month 3, and Month 7 about how the participant's anxiety is
      affecting his or her relationships.

      After the 16-week period, participants will again be randomly assigned to receive either
      continued escitalopram or a placebo for an additional 28 weeks. Participants assigned to the
      placebo will be gradually tapered off escitalopram over a 6-week period. Participants who
      were receiving CBT will receive three more sessions. Throughout the study, participants will
      be asked to complete various assessments, including questionnaires, memory and thinking
      tests, and attention evaluations. Blood samples will be taken at Weeks 2 and 8, and saliva
      samples will be taken at baseline and Weeks 12, 28, and 56.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Anxiety Rating Scale</measure>
    <time_frame>56 weeks</time_frame>
    <description>The Hamilton Anxiety Rating Scale is a clinician-rated measure of cognitive and somatic anxiety symptoms. It consists of 14 items, each of which is scored on a 0-4 scale, summed for a total score ranging from 0 to 56. Inclusion criteria for this study included a Hamilton score &gt;= 17. The Hamilton, administered by blind raters, will be used to test hypotheses number 1 and 2. The outcome of interest is the number of participants who relapse, defined as having a Hamilton increase of &gt;=5, for a total Hamilton &gt;=14, relative to the end of the continuation phase (week 28), for a duration of at least 2 weeks, plus both clinician's and participant's judgment that the participant is experiencing a recurrence of anxiety symptoms. HAMA scores range from 0 (no anxiety) to 56 (high anxiety).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penn State Worry Questionnaire</measure>
    <time_frame>56 weeks</time_frame>
    <description>The Penn State Worry Questionnaire is a 16-item measure of pathological worry. Scores range from 16-80, with higher scores indicating higher levels of worry.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>CBT/Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No CBT/escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No CBT/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo
12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>20 mg daily oral escitalopram</description>
    <arm_group_label>CBT/Escitalopram</arm_group_label>
    <arm_group_label>No CBT/escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill of daily oral escitalopram</description>
    <arm_group_label>CBT/placebo</arm_group_label>
    <arm_group_label>No CBT/placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy (CBT)</intervention_name>
    <description>16 weekly 1-hour sessions</description>
    <arm_group_label>CBT/Escitalopram</arm_group_label>
    <arm_group_label>CBT/placebo</arm_group_label>
    <other_name>CBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Principal (i.e., most severe or pressing problem) or co-principal current diagnosis of
             generalized anxiety disorder

          -  Pretreatment score of at least 17 on Hamilton Anxiety Rating Scale

        Exclusion Criteria:

          -  Principal diagnosis other than GAD

          -  Clinically judged too psychiatrically unstable to participate in the study

          -  Cognitive impairment or dementia

          -  Alcohol or other substance use disorder within 6 months prior to study entry

          -  Lifetime diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or
             bipolar disorder

          -  Serious, unstable, or terminal medical condition that would compromise study
             participation or preclude the use of escitalopram, as determined by a review of
             medical records

          -  Use of psychotropics that could not be safely tapered and discontinued for at least 2
             weeks prior to study entry

          -  Use of depot neuroleptics within 6 weeks prior to study entry

          -  Unwillingness to terminate other forms of psychotherapy

          -  Already received adequate trial of escitalopram or CBT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie L. Wetherell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD and VMRF/VASDHS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Outpatient Psychiatric Services</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>September 3, 2014</results_first_submitted>
  <results_first_submitted_qc>July 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2016</results_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram + CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
        </group>
        <group group_id="P2">
          <title>Escitalopram + no CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram</description>
        </group>
        <group group_id="P3">
          <title>Placebo + CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
        </group>
        <group group_id="P4">
          <title>Placebo + no CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>please see Wetherell et al. (2013), Antidepressant Medication Augmented with Cognitive-Behavioral Therapy for Generalized Anxiety Disorder in Older Adults, American Journal of Psychiatry, 170:782-9.</population>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram + CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
        </group>
        <group group_id="B2">
          <title>Escitalopram + no CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram</description>
        </group>
        <group group_id="B3">
          <title>Placebo + CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
        </group>
        <group group_id="B4">
          <title>Placebo + no CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="7.7"/>
                    <measurement group_id="B2" value="70.3" spread="8.6"/>
                    <measurement group_id="B3" value="70.2" spread="8.1"/>
                    <measurement group_id="B4" value="66.9" spread="5.7"/>
                    <measurement group_id="B5" value="69.5" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Anxiety Rating Scale</title>
        <description>The Hamilton Anxiety Rating Scale is a clinician-rated measure of cognitive and somatic anxiety symptoms. It consists of 14 items, each of which is scored on a 0-4 scale, summed for a total score ranging from 0 to 56. Inclusion criteria for this study included a Hamilton score &gt;= 17. The Hamilton, administered by blind raters, will be used to test hypotheses number 1 and 2. The outcome of interest is the number of participants who relapse, defined as having a Hamilton increase of &gt;=5, for a total Hamilton &gt;=14, relative to the end of the continuation phase (week 28), for a duration of at least 2 weeks, plus both clinician's and participant's judgment that the participant is experiencing a recurrence of anxiety symptoms. HAMA scores range from 0 (no anxiety) to 56 (high anxiety).</description>
        <time_frame>56 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + CBT</title>
            <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram + no CBT</title>
            <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram</description>
          </group>
          <group group_id="O3">
            <title>Placebo + CBT</title>
            <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
          </group>
          <group group_id="O4">
            <title>Placebo + no CBT</title>
            <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Anxiety Rating Scale</title>
          <description>The Hamilton Anxiety Rating Scale is a clinician-rated measure of cognitive and somatic anxiety symptoms. It consists of 14 items, each of which is scored on a 0-4 scale, summed for a total score ranging from 0 to 56. Inclusion criteria for this study included a Hamilton score &gt;= 17. The Hamilton, administered by blind raters, will be used to test hypotheses number 1 and 2. The outcome of interest is the number of participants who relapse, defined as having a Hamilton increase of &gt;=5, for a total Hamilton &gt;=14, relative to the end of the continuation phase (week 28), for a duration of at least 2 weeks, plus both clinician's and participant's judgment that the participant is experiencing a recurrence of anxiety symptoms. HAMA scores range from 0 (no anxiety) to 56 (high anxiety).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank test = 32.67, df = 3</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Penn State Worry Questionnaire</title>
        <description>The Penn State Worry Questionnaire is a 16-item measure of pathological worry. Scores range from 16-80, with higher scores indicating higher levels of worry.</description>
        <time_frame>56 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + CBT</title>
            <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram + no CBT</title>
            <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram</description>
          </group>
          <group group_id="O3">
            <title>Placebo + CBT</title>
            <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
          </group>
          <group group_id="O4">
            <title>Placebo + no CBT</title>
            <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram</description>
          </group>
        </group_list>
        <measure>
          <title>Penn State Worry Questionnaire</title>
          <description>The Penn State Worry Questionnaire is a 16-item measure of pathological worry. Scores range from 16-80, with higher scores indicating higher levels of worry.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" spread="2.6"/>
                    <measurement group_id="O2" value="53.4" spread="10.3"/>
                    <measurement group_id="O3" value="54.4" spread="11.7"/>
                    <measurement group_id="O4" value="57.7" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Beta = -0.48, 95% CI = -0.84 to -0.11</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram + CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
        </group>
        <group group_id="E2">
          <title>Escitalopram + no CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks maintenance escitalopram
Escitalopram: 20 mg daily oral escitalopram</description>
        </group>
        <group group_id="E3">
          <title>Placebo + CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks cognitive behavioral therapy plus continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram
Cognitive behavioral therapy (CBT): 16 weekly 1-hour sessions</description>
        </group>
        <group group_id="E4">
          <title>Placebo + no CBT</title>
          <description>12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo
Escitalopram: 20 mg daily oral escitalopram
Placebo: Placebo pill of daily oral escitalopram</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Julie Wetherell</name_or_title>
      <organization>Veterans Medical Research Foundation</organization>
      <phone>858-552-8585 ext 2752</phone>
      <email>jwetherell@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

